Status:
COMPLETED
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
Lead Sponsor:
UCB Pharma
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 \[NCT00245765\] and Week 12 of re-treatment in this study.
Eligibility Criteria
Inclusion
- Subject having responded to treatment at Week 12 in study C87040 and having relapsed during the follow-up period
- Female subjects either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception.Subjects agreed to continue using adequate contraception during the study and for 12 weeks after the last dose of CDP870
Exclusion
- Subjects with erythrodermic, guttate, generalized pustular form of psoriasis
- Any recent serious or life-threatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough)
- Positive hepatitis B surface antigen test and /or hepatitis C antibody test results
- Positive human immunodeficiency virus (HIV) test result
- White blood cell counts less than 4000 per cubic millimeter or more than 20000 per cubic millimeter
- Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)
- Systemic Lupus Erythematosus
- Participation in a clinical study within the past 3 months except Study C87040
- Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00329303
Start Date
April 1 2006
End Date
May 1 2007
Last Update
May 6 2019
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Besançon, France
2
Créteil, France
3
Nice, France
4
Paris, France